Journal of Microbiology and Biotechnology
The Korean Society for Microbiology and Biotechnology publishes the Journal of Microbiology and Biotechnology.

2019 ; Vol.29-4: 651~657

AuthorYong Won Shin, Ki-Hwan Chang, Gwang-Won Hong, Sang-Gu Yeo, Youngmee Jee, Jong-Hyun Kim, Myoung-don Oh, Dong-Hyung Cho, Se-Ho Kim
Place of dutyR&D Center, GC Pharma, Yongin 16924, Republic of Korea
TitleSelection of Vaccinia Virus-Neutralizing Antibody from a Phage-Display Human-Antibody Library
PublicationInfo J. Microbiol. Biotechnol.2019 ; Vol.29-4
AbstractAlthough smallpox was eradicated in 1980, it is still considered a potential agent of biowarfare and bioterrorism. Smallpox has the potential for high mortality rates along with a major public health impact, eventually causing public panic and social disruption. Passive administration of neutralizing monoclonal antibodies (mAbs) is an effective intervention for various adverse reactions caused by vaccination and the unpredictable nature of emerging and bioterrorist-related infections. Currently, vaccinia immune globulin (VIG) is manufactured from vaccinia vaccine-boosted plasma; however, this production method is not ideal because of its limited availability, low specific activity, and risk of contamination with blood-borne infectious agents. To overcome the limitations of VIG production from human plasma, we isolated two human single chain variable fragments (scFvs) (SC34 and SC212) bound to vaccinia virus (VACV) from a scFv phage library constructed from the B cells of VACV vaccine-boosted volunteers. The scFvs were converted to human IgG1 (VC34 and VC212). These two anti-VACV mAbs were produced in Chinese Hamster Ovary (CHO) DG44 cells. The binding affinities of VC34 and VC212 were estimated by competition ELISA to IC50 values of 2 μg/mL (13.33 nM) and 22 μg/mL (146.67 nM), respectively. Only the VC212 mAb was proven to neutralize the VACV, as evidenced by the plaque reduction neutralization test (PRNT) result with a PRNT50 of ~0.16 mg/mL (~1.07 µM). This VC212 could serve as a valuable starting material for further development of VACV-neutralizing human immunoglobulin for a prophylactic measure against post-vaccination complications and for post-exposure treatment against smallpox.
Full-Text
Key_wordMonoclonal antibody, phage display, single chain variable fragment (scFv), smallpox, vaccinia virus, vaccinia immunoglobulin
References
  1. Walsh SR, Dolin R. 2011. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors. Expert. Rev. Vaccines 10: 1221-1240.
    CrossRef
  2. Moore ZS, Seward JF, Lane JM. 2006. Smallpox. Lancet 367:425-435.
    CrossRef
  3. Lustig S, Maik-Rachline G, Paran N, Melamed S, Israely T, Erez N, et al. 2009. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 27: 1691-1699
    CrossRef
  4. Wittek R. 2006. Vaccinia immune globulin: current policies, preparedness, and product safety and efficacy. Int. J. Infect. Dis. 10: 193-201.
    CrossRef
  5. Prescribing Information of CNJ-016, Vaccinia Immune Globulin Intravenous (Human), sterile solution. Emergent BioSolutions (https://www.emergentbiosolutions. com/sites/default/files/inline-files/LBL040011.pdf).
  6. Schmaljohn C, Cui Y, Kerby S, Pennock D, Spik K. 1999. Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phagedisplay combinatorial library. Virology 258: 189-200.
    CrossRef
  7. Frenzel A, Schirrmann T, Hust M. 2016. Phage-displayderived human antibodies in clinical development and therapy. MAbs 8: 1177-1194.
    CrossRef
  8. Hammers CM, Stanley J Jr. 2014. Antibody phage display:technique and applications. J. Invest. Dermatol. 134: 1-5.
    CrossRef
  9. Kim SH, Park SY. 2002. Selection and characterization of human antibodies against hepatitis B virus surface antigen (HBsAg) by phage-display. Hybrid. Hybridomics 21: 385-392.
    CrossRef
  10. Kim SH, Titlow CC, Margolies MN. 2000. An approach for preventing recombination-deletion of the 40-50 anti-digoxin antibody V(H) gene from the phage display vector pComb3. Gene 241: 19-25.
    CrossRef
  11. Kim SH, Song SH, Kim YJ, Park SY. 2001. Expression and characterization of a recombinant Fab fragment derived from an anti-human alpha-fetoprotein monoclonal antibody. Mol. Cells. 11: 158-163.
  12. Shin YW, Ryoo KH, Hong KW, Chang KH, Choi JS, So M, et al. 2007. Human monoclonal antibody against Hepatitis B virus surface antigen (HBsAg). Antiviral Res. 75: 113-120.
    CrossRef
  13. Kim SH, Chun JH, Park SY. 2001. Characterization of monoclonal antibodies against carcinoembryonic antigen (CEA) and expression in E. coli. Hybridoma 20: 265-272.
    CrossRef
  14. Borges MB, Kato SE, Damaso CR, Moussatché N, da Silva Freire M, Lambert Passos SR, et al. 2008. Accuracy and repeatability of a micro plaque reduction neutralization test for vaccinia antibodies. Biologicals 36: 105-110.
    CrossRef
  15. Chen Z, Earl P, Americo J, Damon I, Smith SK, Zhou YH, et al. 2006. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. USA 103:1882-1887.
    Pubmed CrossRef Pubmed Central
  16. Chen Z, Earl P, Americo J, Damon I, Smith SK, Yu F, et al. 2007. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J. Virol. 81: 8989-8995.
    CrossRef
  17. Schmaljohn C, Cui Y, Kerby S, Pennock D, Spik K. 1999. Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phagedisplay combinatorial library. Virology 258: 189-200.
    CrossRef
  18. Tikunova NV, Morozova VV, Batanova TA, Belanov EF, Bormotov NI, Ilyichev AA. 2001. Phage antibodies from combinatorial library neutralize vaccinia virus. Hum. Antibodies 10: 95-99.
    CrossRef
  19. McCausland MM, Benhnia MR, Crickard L, Laudenslager J, Granger SW, Tahara T, et al. 2010. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir. Ther. 15: 661-675.
    CrossRef



Copyright © 2009 by the Korean Society for Microbiology and Biotechnology.
All right reserved. Mail to jmb@jmb.or.kr
Online ISSN: 1738-8872    Print ISSN: 1017-7825    Powered by INFOrang.co., Ltd